Pulse Biosciences, Inc Common Stock (DE) (PLSE) Stock
Key stats
- Market cap
- $3.30B
- Price / Earnings ratio
- -43.2x
- EPS (TTM)
- -$1.18
- Volume
- Loading
- 52-week high
- $58.90
- 52-week low
- $12.56
Source: third-party data provider, as of October 16, 2026
Compare with PLSE
Recent news

Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
PLSE

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PLSE

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
PLSE

Why Pulse Biosciences Stock Popped Today
Why Pulse Biosciences Stock Popped Today
PLSE
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 41.63
- MACD 12/26/9
- -0.01
- EMA 9 of MACD
- 0.56
- MACD histogram
- -0.57
- SMA 50
- $49.33
- Price below SMA 50
- EMA 50
- $47.36
- Price below EMA 50
- SMA 200
- $29.14
- Price above SMA 200
- EMA 200
- $32.05
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 14, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
PLSE

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PLSE

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
PLSE

Why Pulse Biosciences Stock Popped Today
Why Pulse Biosciences Stock Popped Today
PLSE

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PLSE

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PLSE

Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform
Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform
PLSE

Pulse Biosciences Q2 Earnings Call Highlights
Pulse Biosciences Q2 Earnings Call Highlights
PLSE

Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Misses Revenue Estimates
Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Misses Revenue Estimates
PLSE

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
PLSE
News tone: automated (AI) classification of the article's content, not a price prediction.
About Pulse Biosciences, Inc Common Stock (DE)
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Paul Arthur LaViolette M.B.A. | President, CEO & Co-Chairman of the Board | 1958 |
| Mr. Jon Skinner | Chief Financial Officer | 1986 |
| Ms. Liane Teplitsky | Chief Operating Officer | 1977 |
| Mr. Darrin R. Uecker | CTO & Director | 1966 |
| Mr. Steven T. Weber | VP of Accounting, Principal Accounting Officer & Global Corporate Controller | 1976 |
| Mr. Kenneth B. Stratton Esq., J.D. | General Counsel & Corporate Secretary | 1969 |
| Ms. Patty Perla | Vice President of Human Resources | — |
| Mr. David Danitz | Senior Vice President of Engineering | — |
| Dr. Gansevoort Dunnington M.D. | Chief Medical Officer | — |
| Dr. Niv Ad M.D. | Chief Science Officer of Cardiac Surgery | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 16, 2026
Technical indicators
- RSI 14
- 41.63
- MACD 12/26/9
- -0.01
- EMA 9 of MACD
- 0.56
- MACD histogram
- -0.57
- SMA 50
- $49.33
- Price below SMA 50
- EMA 50
- $47.36
- Price below EMA 50
- SMA 200
- $29.14
- Price above SMA 200
- EMA 200
- $32.05
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 14, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $58.00
- Average
- $63.80
- High
- $73.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -20.9 | +14.5 | -8.1 | +20.0 | +12.4 | +24.0 | +33.4 | -4.2 | -7.0 |



